partnering for success, page-27

Morning Playez. Mate your barking up the wrong tree- with the greatest respect- one has nothing to do with the other.
refer BSW earlier post which articulates this much better than I could. This paper was very specific to Oncology and the challenges pertaining to this field. The points raised have in my view zero to do with POHs strategy and business plan for Oxy.

You must remember that POH has put together an advisory team which includes ex FDA personal... POH has annced that top-level regulatory advisors have responded favourably to the trial results and path to registration. POHs senior advisor is Lee S Simon MD, a former Division Director of Analgesic,Anti-inflammatory and Ophthalmologic Drug Products (DAAODP) at the FDA.....have some faith old son- we are in very good hands here.